Premium
Early effects of inhaled steroids on airway hyperreactivity and pulmonary function in asthma
Author(s) -
Sherrington Colin A.,
Mallol Javier
Publication year - 1999
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/(sici)1099-0496(199906)27:6<376::aid-ppul3>3.0.co;2-y
Subject(s) - medicine , asthma , bronchial hyperreactivity , airway , pulmonary function testing , inhaled corticosteroids , respiratory disease , intensive care medicine , immunology , anesthesia , lung
While inhaled steroids (IS) are increasingly recognized as having a more rapid onset of action than was once thought, little is known about the early changes in objective measures of respiratory function that follow the inhalation of repeated doses. These early effects were examined in a randomized, double‐blind, placebo‐controlled, crossover study of 20 children aged 10–16 years with stable mild asthma. Beclomethasone dipropionate (BDP) 2,000 mcg, fluticasone propionate (FP) 400 mcg, and placebo were given twice daily for three doses. Airway hyperreactivity (AHR) to methacholine (PC 20 ), pulmonary function tests (PFT: FVC, FEV 1 , FEF 25–75% ), and the rate of recovery from methacholine‐induced bronchospasm following administration of salbutamol were determined at 8 h (after 1 dose) and at 32 h (after three doses). At 8 h, minor improvements in AHR were demonstrated, averaging 0.32 doubling doses in PC 20 . At 32 h, significant improvements in AHR and PFTs were present, averaging 0.92 doubling doses in PC 20 , 3.96% of predicted values in FEV 1 , and 7.74% of predicted values in FEF 25–75% . No significant changes occurred in FVC. There were no significant differences between the effects of BDP and FP. Inhaled steroids were associated with a slower response to salbutamol following methacholine challenge testing at 32 h. We conclude that IS, given in repeated high doses, result in significant improvements within 32 h in both AHR and PFTs, along with changes in response to β 2 agonists. These effects are likely to be the result of the topical activity of IS. Pediatr Pulmonol. 1999; 27:376–382. © 1999 Wiley‐Liss, Inc.